{
    "Trade/Device Name(s)": [
        "DiviTumTKa",
        "DiviTum\u00aeTKa",
        "DiviTum\u00ae"
    ],
    "Submitter Information": "Biovica International AB",
    "510(k) Number": "K202852",
    "Predicate Device Reference 510(k) Number(s)": [
        "K100831"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QTE"
    ],
    "Summary Letter Date": "April 28, 2022",
    "Summary Letter Received Date": "May 2, 2022",
    "Submission Date": "April 7, 2021",
    "Regulation Number(s)": [
        "21 CFR 866.6010"
    ],
    "Regulation Name(s)": [
        "Tumor-Associated Antigen Immunological Test System"
    ],
    "Analyte Class(es)": [
        "cancer molecular",
        "immunology"
    ],
    "Analyte(s)": [
        "Thymidine kinase activity (TKa)"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "ELISA Plate Reader (405 nm and 630 nm)"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme-linked immunosorbent assay (ELISA)",
        "Enzyme immunoassay (EIA)",
        "Colorimetric detection"
    ],
    "Methodologies": [
        "Semiquantitative enzyme immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for Biovica DiviTumTKa ELISA assay to measure thymidine kinase activity in serum as an aid to monitor disease progression in metastatic breast cancer patients.",
    "Indications for Use Summary": "DiviTumTKa is intended for semiquantitative measurement of thymidine kinase activity in human serum to aid in monitoring disease progression in previously diagnosed hormone receptor positive, metastatic postmenopausal female breast cancer patients; results should be used with other clinical methods.",
    "fda_folder": "Immunology"
}